Propranolol Use Inversely Linked to Melanoma Recurrence

Share this content:
Propranolol Use Inversely Linked to Melanoma Recurrence
Propranolol Use Inversely Linked to Melanoma Recurrence

THURSDAY, Sept. 28, 2017 (HealthDay News) -- For patients with melanoma, use of propranolol is associated with reduced risk of recurrence, according to a study published online Sept. 28 in JAMA Oncology.

Vincenzo De Giorgi, M.D., from the University of Florence in Italy, and colleagues conducted a prospective study involving melanoma patients treated with propranolol for off-label use. Patients with histologically confirmed stage IB and IIIA cutaneous melanoma and no evidence of metastases were asked to take propranolol as an off-label adjuvant treatment at the time of diagnosis. If they accepted, they were considered part of the propranolol cohort (19 patients); those who refused treatment but agreed to participate in the control group were considered part of the nonpropranolol cohort (34 patients).

The researchers found that the use of propranolol at the time of diagnosis was significantly inversely linked to melanoma recurrence after adjustment for known prognostic factors, with about an 80 percent reduction in risk for propranolol users (hazard ratio, 0.18).

"These results confirm recent observation that β-blockers protect patients with thick cutaneous melanoma from disease recurrence," the authors write. "Repurposing the vast arsenal of approved drugs with a nononcology primary purpose may prove an attractive and inexpensive strategy for offering more effective treatment options to patients with cancer."

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

FDA Approves First Drug for Rare Form of Rickets

FDA Approves First Drug for Rare Form of ...

Crysvita approved for adults and children ages 1 year and older with x-linked hypophosphatemia

High FGF-23 Linked to Recurrent Cardiac Events After ACS

High FGF-23 Linked to Recurrent Cardiac Events After ...

FGF-23 in top quartile independently linked to greater risk of CV death, heart failure hospitalization

Medical Cannabis Not Recommended for Sleep Apnea

Medical Cannabis Not Recommended for Sleep Apnea

American Academy of Sleep Medicine says evidence insufficient to recommend cannabis for apnea

is free, fast, and customized just for you!

Already a member?

Sign In Now »